Watermark
  Back to Search Results

BGB-A317-301

Completed

Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC

BeOne Study ID Info icon SVG graphic used for tooltips or additional information.

BGB-A317-301

ClinicalTrials.gov ID Info icon SVG graphic used for tooltips or additional information.

NCT03412773

EudraCT Number Info icon SVG graphic used for tooltips or additional information.

2017-002423-19

China Drug Trials ID Info icon SVG graphic used for tooltips or additional information.

CTR20170882

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Plain Language Summary

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Plain Language Summary